B.R.I.A.

BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, with a primary emphasis on metastatic breast cancer. The company's lead clinical candidate, Bria-IMT, is a whole-cell therapeutic vaccine engineered to express GM-CSF and stimulate a targeted immune response against cancer cells; it is currently being evaluated in a pivotal Phase 3 clinical trial (BRIA-ABC). BriaCell also leverages its Bria-OTS platform to provide personalized, off-the-shelf immunotherapies based on patient-specific HLA types, aiming to offer high-precision treatment without the logistical complexities of traditional personalized cell therapies. The company's pipeline is further supported by a small molecule program targeting PKC delta and a monoclonal antibody program targeting B7-H3.